InnovHeart Appoints Jason M. Bottiglieri as New Chief Executive Officer and Member of the Board

MILAN, Dec. 19, 2018 /PRNewswire/ -- InnovHeart s.r.l., a developer of novel transcatheter mitral valve replacement (TMVR) systems for the treatment of cardiac disease, is very pleased to announce the appointment of experienced medical device executive Jason Bottiglieri to the role of Chief Executive Officer of the company and executive member of the Board of Directors. Former CEO and founder, Giovanni Righini, will continue to serve the company as Chief Technology Officer and as member of the Board.

Jason Bottiglieri has more than 22 years of experience in the medical device industry including 18 in the interventional cardiovascular market. Before joining InnovHeart, Mr. Bottiglieri was Chief Executive Officer of Infraredx, a start-up company developing a novel intravascular imaging system for the detection of lipid core plaque in coronary artery disease. Under Jason's leadership, Infraredx was acquired by Nipro Corporation, confirming him as CEO of the Company. Prior to Infraredx, Mr. Bottiglieri was one of the founding US sales leaders in the Italy-based Invatec company. During this period Invatec was acquired by Medtronic and became the foundation of its peripheral vascular business unit.  Mr. Bottiglieri's management experience also includes leadership positions at Spectranetics Corp. and Cordis, a Johnson & Johnson Company, where he directed global training and was part of a core team assembled to launch the world's first drug- eluting stent (Cypher). 

Mr. Bottiglieri Commented, "The Saturn mitral valve and delivery system is very unique with clinically important features that could prove game changing for patients. Under Giovanni's leadership the company has made extraordinary advancements in a very short time frame. I am honored and inspired by the opportunity to join this talented team and look forward to making InnovHeart's technology the gold standard for mitral valve replacement."

Dr Keith Dawkins, Chairman of the company added, 'We are delighted that Jason has joined InnovHeart. He brings an impressive medical device industry skill-set that will fit well with the company philosophy. It is an important time for InnovHeart, and I am confident that under Jason's leadership, we will realize the goal of bringing our unique minimally invasive Saturn technology to the treatment of patients with mitral valve disease.

About InnovHeart

InnovHeart s.r.l., with operations in Colleretto Giacosa (Italy) and Poway (CA-USA), develops the Saturn System, a transcatheter mitral valve replacement (TMVR) platform intended to treat patients suffering from mitral valve disease. Saturn's unique design allows the clinician to accurately deliver the prosthesis in the anatomically correct position, providing a stable and durable anchorage and sealing to the implant site. The system's sub-annular ring affords inverse remodeling of the mitral annulus, and the low profile of the prosthesis ensures unimpeded flow from the left ventricle after implantation.

The Company is in late preclinical development of the Saturn TA System designed for trans-apical delivery, and planned to enter human use the first half of next year. A trans-septal system is also in development and will enter human studies following transapical validation.

InnovHeart is backed by leading investor Genextra S.p.A, Italian holding company specialized in early-stage investments in the life sciences sector.

Additional information at www.innovheart.com.

Media contact:

Sonia Hardman
[email protected] 
+390236515110

SOURCE InnovHeart s.r.l.